Jefferies maintains Parexel at underperform

Parexel International Corp. was maintained by Jefferies & Co. Inc. analyst David Windley at an underperform rating with a $17.25 price target after first-quarter results showed lower-than-expected revenue. The company managed to meet earnings per share estimates, but Jefferies said the trends don't show good health. Shares of the Waltham, Mass.-based biopharmaceutical company were down $0.76, or 3.45%, at $21.24 on volume of 150,879 shares versus the three-month running average of 123,770 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.